2026 EAEU Regulatory Calendar: Drug and Medical Device Registration Deadlines by Quarter
Every Regulatory Affairs director keeps a planner on their desk covered in red marks. In 2026, those marks are more numerous than usual. The pharmaceutical industry has crossed the January 1st threshold, medical devices are entering the decisive phase of the EAEU transition, and the Chestny ZNAK (Russia’s national drug track-and-trace system) is expanding to new product categories.
Simultaneously, GMP — Good Manufacturing Practice — inspection rules are shifting, pharmacovigilance requirements are being updated, and new monographs of the EAEU Pharmacopoeia are entering into force. I have compiled all the year’s principal deadlines, broken down by quarter and market sector, into a single reference. This is a roadmap for planning the workload of regulatory departments. The material will be of use to RA Directors, Heads of Registration, Quality Assurance specialists, and Pharmacovigilance officers.
The Regulatory Landscape Before 2026
For the past eight years, the Eurasian Economic Union (EAEU) pharmaceutical market operated under a dual-standard regime. On one hand, the Rules for Registration and Examination of Medicines — adopted by EEC (Eurasian Economic Commission) Council Decision No. 78 of November 3, 2016 — were in effect. On the other, national Marketing Authorizations (MAs) remained valid under transitional provisions.
Regulators extended deadlines several times: the original cut-off of December 31, 2020 moved to 2021, then to 2025. That duality created a comfort zone for manufacturers. Companies could register products through simplified national procedures in 90–120 business days while postponing the switch to EAEU procedures — 160 business days plus the time needed to prepare a registration dossier in CTD (Common Technical Document) format — indefinitely.
According to the Ministry of Health of the Russian Federation, by early 2025 only approximately 4,500 (25%) of the roughly 18,000 active MAs for medicinal products were issued under EAEU procedures. The remaining 75% continued to operate on the basis of national MAs.
The situation for medical devices (MDs) followed a similar pattern. The Agreement on Uniform Principles and Rules for the Circulation of Medical Devices within the EAEU has been in force since 2015, and the Registration Rules (EEC Council Decision No. 46) entered into force in 2017. National MAs for medical devices, however, retained validity under transitional provisions. Article 38 of Federal Law No. 323-FZ «On the Fundamentals of Health Protection of Citizens» preserved the right to market MDs under national registration until a specified date.
The EAEU Pharmacopoeia became effective in March 2021, with the first part of Volume I. Manufacturers were given a five-year period to bring their quality specifications into line with Union Pharmacopoeia requirements. That period expired on January 1, 2026.
GMP certification also went through several harmonization stages. Since 2022, EAEU member states have issued GMP certificates (compliance conclusions) under the EAEU Good Manufacturing Practice Rules (EEC Council Decision No. 77 of November 3, 2016). In Russia, Minpromtorg — the Ministry of Industry and Trade — became the authorized body for issuing these certificates, under Government Decree No. 1446 of September 15, 2020.
As of January 1, 2026, the landscape has changed materially. Federal Law No. 61-FZ «On the Circulation of Medicines» received further amendments to Article 47, extending the special import regime until December 31, 2027. Legislators made the signal unmistakable: this is the final extension.
What Has Changed: The Quarterly Calendar
Q1 — First Quarter
January 1, 2026 is a landmark date for the Russian and EAEU markets. Formally, the transition period for medicinal products has concluded. However, the amendments to Article 47 of Law No. 61-FZ that entered into force on the same date allow products holding national MAs to remain in circulation until the end of 2027, provided certain conditions are met.
In practice: medicinal products manufactured before December 31, 2025 under a national MA may be sold through pharmacy networks and healthcare organizations until their expiry date. Production of new batches is permitted only where the manufacturer holds an EAEU MA, has a pending EAEU registration application under the «3+2» mechanism, or has submitted a written commitment to bring the dossier into compliance with EAEU requirements within set timelines.
Government Decree No. 593 of June 29, 2021 «On Transitional Provisions» defines the conditions for operating during the transition period.
The «3+2» mechanism allows companies that have filed for EAEU MA to continue production throughout the application review period — up to three years under the standard procedure — plus two additional years after a rejection to address deficiencies or complete the procedure. In effect, this gives manufacturers up to five years from the date of filing.
Alongside this, from January 1, 2026 MAs for medicinal products are issued exclusively in electronic form through the Unified State Services Portal (EPGU). Paper MAs and their duplicates are no longer issued. Information on registered products is published in the State Register of Medicines in electronic form.
A tax reform also took effect on January 1, 2026: the base VAT rate in Russia increased to 22% (Federal Law No. 425-FZ). The preferential 10% rate for medicines and medical devices is retained, but all ancillary services — logistics, consulting, IT — are now taxed at the higher rate. This raises the cost of registration procedures by 5–10%.
January 10, 2026 marked the end of the transition to updated MRLs — Maximum Residue Levels — for veterinary medicinal products (VMPs) in food products, under TR CU 021/2011 «On Food Safety.» The controlled substances include antibiotics (tetracycline group, penicillins, aminoglycosides), hormones, and anthelmintics. Feed additive manufacturers, veterinary supplement producers, and livestock product companies were required to bring their quality control systems into line with the updated requirements.
March 1, 2026 sees mandatory Chestny ZNAK digital marking launched for two new product categories: VMPs in all dosage forms, with mandatory unit-level accounting via electronic data interchange (EDI); and dietary supplements (BAAs, БАД) in specific categories, including vegetable fats and oils, enzyme preparations, and probiotics.
Marking requirements include application of a DataMatrix 2D barcode to each unit and full integration with the EDI system. The marking operator (CRPT) sets technical requirements for code application, data formats, and timelines for reporting items entering and leaving circulation.
Table 1: Key Events of Q1 2026
| Event | Date | Action Required | Responsible |
|---|---|---|---|
| End of formal drug transition period | Jan 1, 2026 | Audit the MA status of every product in the portfolio | RA Department |
| Electronic MAs only | Jan 1, 2026 | Configure EPGU access for tracking | IT / RA Department |
| VAT increase to 22% | Jan 1, 2026 | Recalculate registration procedure budgets | Finance |
| Updated VMP MRLs | Jan 10, 2026 | Audit residue levels across the product range | Quality Assurance |
| Chestny ZNAK: VMPs and BAAs | Mar 1, 2026 | Deploy EDI and DataMatrix marking equipment | Production / Logistics |
Q2 — Second Quarter
April 2026 will bring an update to the «Pharma 2030» state strategy. Minpromtorg has scheduled a revision of the pharmaceutical industry development programme, with adjustments to the support measures for domestic manufacturers. The expected changes include:
Tightening of the «second odd man out» rule for state procurement: where two or more Russian manufacturers enter the same tender with equivalent products, foreign bids are automatically rejected. The list of dosage forms covered by this rule will be expanded.
Localization criteria are also being tightened. To qualify as a «Russian manufacturer,» production of the finished dosage form on Russian territory will be mandatory; API (Active Pharmaceutical Ingredient) synthesis is the next stage requirement. Packaging in Russia alone will no longer be sufficient grounds.
The list of products whose domestic production is strategically mandatory will be updated. The VED list (Vital and Essential Drugs, ЖНВЛП) will be supplemented to reflect lessons from the COVID-19 pandemic and current geopolitical conditions.
May 26, 2026 is a date that matters for companies exporting to the European Union. The transition period under EU MDR — Medical Device Regulation 2017/745 — closes for Class III custom-made implantable devices. CE marks issued under the old MDD and AIMD directives lose validity. Russian manufacturers targeting the EU market must recertify with a Notified Body under MDR requirements, update technical documentation, implement UDI (Unique Device Identification), and register in the EUDAMED database. Recertification takes 6 to 18 months depending on the device’s risk class. Companies that have not completed the switch by May 26 will lose the right to sell on the EU market.
June 2026 will bring mass inspections of PSMF — Pharmacovigilance System Master Files. The EEC announced scheduled inspections of EAEU MA holders for compliance with GVP — Good Vigilance Practice — Rules. Companies that received EAEU MAs in 2024–2025 fall into the first inspection wave. Inspectors will assess:
- presence and currency of the PSMF;
- qualifications and availability of the QPPV — Qualified Person for Pharmacovigilance;
- functioning of the adverse reaction (AR) collection and processing system;
- timely submission of expedited reports (15 calendar days for serious adverse reactions with a fatal outcome) and PSUR — Periodic Safety Update Reports;
- implementation of the RMP — Risk Management Plan — where required.
Sanctions for non-compliance range from formal warnings to suspension of the product’s circulation across the EAEU. Regulators have been particularly attentive to ICSR (Individual Case Safety Report) submission deadlines and the existence of contractual agreements with local pharmacovigilance operators.
Q3 — Third Quarter
July 2026 is a turning point for the medical device market in Russia and the EAEU. Exactly eighteen months remain until the final transition deadline of December 31, 2027. Given registration procedure timelines, this is the last reasonable moment to begin work on complex devices.
Article 38 of Federal Law No. 323-FZ establishes that from January 2, 2027, the provisions allowing the circulation of certain MD categories without EAEU MA lose force. This covers devices for life-critical care of individual patients, devices for export outside the EAEU, and kits assembled from registered components.
EAEU MD registration under EEC Council Decision No. 46 takes varying amounts of time depending on risk class:
Class 1 (low risk): sterile and measuring devices require full evaluation in 90–120 business days. Non-sterile Class 1 devices register under a simplified procedure in 50 business days.
Class 2a (medium risk): full evaluation takes 120–150 business days. This class covers diagnostic reagents and non-complex therapeutic equipment.
Class 2b (elevated risk): 150–180 business days for evaluation, plus mandatory clinical investigation of medical devices for most products. Long-contact implantable devices and active therapeutic devices fall here.
Class 3 (high risk): 180–220 business days. Implantable devices, combination devices with a medicinal component, devices derived from animal tissue. Clinical investigation is mandatory.
Preparation phases add time on top of evaluation periods. Technical testing in accredited laboratories takes 30–60 business days. Toxicological studies for devices with contact exceeding 30 days require 60–90 days. Clinical investigations (for Classes 2b and 3) run from six months to two years depending on protocol complexity.
Any manufacturer who has not started the procedure by July 2026 faces a very high arithmetical probability of missing the deadline, especially as queues at testing laboratories and expert organizations will grow as the final date approaches.
Table 2: Medical Device Registration Timelines by Risk Class
| MD Class | Registration Timeline | Preparation Time | Last Start Date for Compliance |
|---|---|---|---|
| 1 (low risk) | 90–120 business days | 30–60 days | September 2027 |
| 2a (medium risk) | 120–150 business days | 60–90 days | July 2027 |
| 2b (elevated risk) | 150–180 business days | 6–12 months | January 2027 |
| 3 (high risk) | 180–220 business days | 12–24 months | July 2026 |
September 2026 will bring material changes for SaMD — Software as a Medical Device — and AI/ML-based medical devices. GOST R 72067-2025, regulating medical laboratories using laboratory-developed tests (LDTs), already entered into force on January 1, 2026, directly affecting providers of genetic tests and AI-based diagnostic platforms.
The EEC is preparing updated requirements covering: validation of machine-learning algorithms on representative datasets; post-market surveillance for algorithm performance; documentation of training data, model architecture, and quality metrics; procedures for algorithm changes (when a change triggers re-registration versus when notification suffices); and cybersecurity for connected medical devices.
Manufacturers of SaMD with diagnostic, prognostic, or clinical decision support functions will need to adapt technical documentation to the new testing protocols. Particular attention is given to the explainability of algorithmic decisions and the prevention of systematic bias.
For EU exporters, August 2, 2026 is when the EU AI Act enters into full force. Medical devices incorporating AI are classified as «high-risk» systems and require a complex conformity assessment procedure.
Q4 — Fourth Quarter
October 2026 is expected to bring the adoption of a simplified registration procedure for companion animal veterinary medicinal products (dogs, cats, ornamental rodents, aquarium fish, songbirds). The EEC is preparing a package of decisions to reduce the administrative burden for manufacturers of products that do not enter the human food chain. The simplifications include: a reduced registration dossier volume (fewer residue study requirements); recognition of preclinical and clinical study results conducted in third countries through mutual recognition; shorter evaluation timelines of 90–120 business days; and a simplified variations procedure for minor changes to formulation or manufacturing process. The companion-animal segment grows at 15–20% per year, so veterinary vaccine, antiparasitic, and vitamin supplement manufacturers will be able to bring new products to market faster.
November 2026 is traditionally when new state fee schedules and expert organization tariffs for the following year are published. Trends over the past five years show a consistent increase of 10–15% annually.
Current base state fee rates in Russia (2025 figures): for medicinal products, MA registration runs from ₽180,000 to ₽450,000 (~$1,800–$4,500) depending on category, MA confirmation costs ₽150,000 (~$1,500), and variations (dossier changes) range from ₽25,000 to ₽180,000 (~$250–$1,800). For medical devices, Class 1 MA registration starts at ₽25,000 (~$250), Classes 2a–3 registration costs ₽50,000–₽150,000 (~$500–$1,500), and variations run ₽10,000–₽75,000 (~$100–$750).
State fees are supplemented by expert organization costs — the FSBI NTSESMP for medicinal products, the FSBI VNIIMT for medical devices — plus laboratory testing fees and regulatory consultancy. The total budget for registering a single medicinal product under the EAEU procedure ranges from ₽3 million to ₽15 million (~$30,000–$150,000), depending on dossier complexity and the need for clinical trials. For medical devices, the equivalent range is ₽1 million to ₽8 million (~$10,000–$80,000).
December 31, 2026 is the deadline for submitting PSURs for products that received EAEU MAs during the year. PSUR submission frequency is determined by the reference date and the product’s time on the market: every six months for the first two years after registration, annually from year three through five, and every three years thereafter (or on regulatory request). The year-end is also the time for reconciling the status of all pending variations, conducting a technical audit of registration dossiers, and updating SmPC — Summaries of Product Characteristics.
Comparing EAEU Procedures
Table 3: EAEU Registration Procedure Comparison: Medicinal Products vs. Medical Devices
| Parameter | Medicinal Products | Medical Devices |
|---|---|---|
| Final transition deadline | Dec 31, 2027 | Dec 31, 2027 |
| Base registration timeline | 160 business days | 90–220 business days |
| «3+2» mechanism | Yes, in effect | No |
| Manufacturing requirement | EAEU GMP certificate | QMS per ISO 13485 |
| State fee (base) | From ₽180,000 | ₽25,000–₽150,000 |
| Total registration budget | ₽3–15 million | ₽1–8 million |
| Clinical evidence requirement | Mandatory for new INNs | Classes 2b and 3 |
| Periodic reports | PSUR, PBRER | Safety reports |
| Principal Russian regulator | Ministry of Health | Roszdravnadzor |
Action Plan for the Year
Full portfolio audit, January–February. Build a single register of all products — medicinal products, medical devices, dietary supplements, veterinary medicinal products — showing the MA type (national RF / EAEU / EU), expiry date and last renewal date, dossier status (current / requires update), and GMP certificate or ISO 13485 QMS certificate status for production sites.
Classify products into three zones.
Green: EAEU MA obtained, dossier current, production certified. Yellow: EAEU procedure launched or planned within six months. Red: national MA expiring, EAEU procedure not started, no decision taken.
Define priorities by end of March. For Red Zone products, make a firm decision: transfer to EAEU or withdraw from the portfolio. Relevant criteria are the product’s revenue share and margin, the cost of EAEU registration including any additional studies, the competitive environment (whether analogues with EAEU MAs are already on the market), and strategic plans for the product line.
Launch registration procedures for Class 2b and 3 medical devices immediately. Every month of delay reduces the probability of meeting the 2027 deadline. Map out a schedule with checkpoints: contracts with testing laboratories by February–March 2026; technical testing from April through June 2026; toxicological studies from July through September 2026 (where required); dossier submission in October 2026; evaluation in 2027.
Complete Chestny ZNAK integration by March 1. For VMPs and BAAs in the newly covered categories, verify that DataMatrix marking equipment is installed and tested, that software is integrated with the CRPT marking operator, that EDI is configured with all counterparties, that personnel are trained, and that trial shipments of marked products have been completed.
Prepare for pharmacovigilance inspections before June. Conduct an internal audit: update the PSMF; verify QPPV availability during business hours; confirm that all serious adverse reactions are documented and reported to the database on time; assemble an inspection dossier containing SOPs, personnel training records, and audit logs.
Build the 2027 budget with a 15–20% buffer. Factor in the expected increase in state fees and tariffs, possible additional studies requested by experts, consultancy and legal fees for complex procedures, travel costs for staff attending inspections and regulatory meetings, and a contingency reserve for supplementary data requests and repeat testing.
The 2026 regulatory calendar is dense but fully predictable. The rules were published in advance, the deadlines are set, the procedures are described in the relevant legislation. Companies that begin systematic work in Q1 will reach the end of 2027 with a renewed portfolio and established processes. Leaving decisions until the last moment leads to crisis mode and premium costs for urgency.
Sources: EU Regulation 2024/1689 (EU AI Act); Federal Law No. 61-FZ «On the Circulation of Medicines» (as amended Jan 1, 2026); Federal Law No. 323-FZ «On the Fundamentals of Health Protection of Citizens in the Russian Federation» (as amended Jan 1, 2026); Federal Law No. 425-FZ (VAT 22%); EEC Council Decision No. 78 of Nov 3, 2016 (Rules for Registration and Examination of Medicines); EEC Council Decision No. 77 of Nov 3, 2016 (EAEU GMP Rules); EEC Council Decision No. 46 of Feb 12, 2016 (Rules for Registration and Examination of Medical Devices); Government Decree No. 593 of Jun 29, 2021 (Transitional Provisions for Medicinal Products); Government Decree No. 675 of May 27, 2024 (VMP Marking); Government Decree No. 1446 of Sep 15, 2020 (Authorized Organization); GOST R 72067-2025 (Medical Laboratories — Quality and Competence Requirements); TR CU 021/2011 (On Food Safety); EU MDR 2017/745; EU Regulation 2023/607 (MDR transitional amendments).
Other articles on Regulatory Affairs →